January 20, 2022 Patent filed
“Combination cancer therapy with DYRK1 inhibitors and inhibitors of the RAS-RAF-MEK-ERK (MAPK) pathway”, unpublished, filed January 20, 2022
"Combinations for the treatment of cancer using quiescent cell targeting and inhibitors of mitosis"
“Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors”
"A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects"
"DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3"
April 28, 2020 AACR Annual Meeting
Abstract Number: 5161
Validation of drug candidates targeting dormant cancers in live cells as a key for successful translation into the clinics
March, 2020 Patent granted
Patent "Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases"; WO 2018119039
May 26, 2019 ASCO Annual Meeting Presentation
Abstract Number: 14670
Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma.
April 2, 2019 AACR Annual Meeting Presentation
Abstract Number: 3038
Implications of DYRK1B kinase in ovarian cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for ovarian cancers
February, 2019 Journal of Molecular Modeling
December 1, 2018 ASH Annual Meeting
The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL.
April 4, 2017 AACR Annual Meeting
January 11, 2016 8th Annual BIOTECH Showcase
Date and Time: January 13th 2016 8AM
Location: The Parc 55 San Francisco Track A
© 2019 by Felicitex Therapeutics, Inc »«